tiprankstipranks
Trending News
More News >
Venus Concept (VERO)
NASDAQ:VERO
Advertisement

Venus Concept (VERO) AI Stock Analysis

Compare
497 Followers

Top Page

VERO

Venus Concept

(NASDAQ:VERO)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
$2.50
▲(2.88% Upside)
Venus Concept's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high operational costs, and substantial net losses. Technical analysis provides a neutral outlook, while valuation metrics highlight significant challenges due to negative profitability. Despite some strategic efforts to improve financial health, the company's financial instability remains a major concern.
Positive Factors
Strategic Business Sale
The sale of the Venous Hair business allows Venus Concept to focus on its core medical aesthetics segment, potentially improving revenue growth, lowering operating expenses, and enhancing cash flow, which can strengthen its market position and financial health over the long term.
Cash System Sales Growth
The increase in cash system sales indicates a strategic shift towards higher quality revenue streams. This focus can enhance profitability and cash flow stability, providing a more sustainable financial foundation and competitive edge in the U.S. market.
Debt Reduction
Reducing debt obligations improves financial flexibility and reduces interest expenses, which can enhance long-term financial stability and allow for more strategic investments in growth opportunities.
Negative Factors
Declining Revenue
The decline in revenue, particularly in international sales, indicates challenges in maintaining market share and competitiveness. This trend could impact long-term growth prospects and necessitates strategic adjustments to reverse the decline.
High Operating Expenses
Rising operating expenses without corresponding revenue growth can strain profitability and cash flow. This trend highlights inefficiencies that need addressing to improve operational performance and financial health over the long term.
Gross Margin Decline
A declining gross margin indicates increased cost pressures and reduced pricing power, which can weaken competitive positioning and profitability. Addressing these issues is critical for sustaining long-term financial performance.

Venus Concept (VERO) vs. SPDR S&P 500 ETF (SPY)

Venus Concept Business Overview & Revenue Model

Company DescriptionVenus Concept (VERO) is a global leader in medical aesthetics, specializing in innovative technologies and services for the non-invasive treatment of skin and body concerns. The company operates primarily in the aesthetic device market, providing a range of products that utilize advanced technologies, including radiofrequency and laser systems, to enhance patient outcomes in areas such as body contouring, skin rejuvenation, and hair restoration. Venus Concept's commitment to innovation and customer support has positioned it as a trusted partner for medical professionals and clinics worldwide.
How the Company Makes MoneyVenus Concept generates revenue through multiple streams, primarily by selling its proprietary medical devices and systems to aesthetic practitioners and clinics. These devices are often sold with accompanying service and maintenance agreements, which provide ongoing revenue. Additionally, the company offers consumables and accessories related to their devices, creating a recurring revenue model. Partnerships with aesthetic practices and medical professionals also enhance their market reach and revenue potential. Furthermore, Venus Concept may benefit from collaborations with research institutions and participation in clinical trials to validate and promote the effectiveness of its products, driving further sales and brand recognition.

Venus Concept Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 13, 2025
Earnings Call Sentiment Neutral
The earnings call presents a mixed picture with notable strategic achievements such as sequential growth and a significant business sale, but also highlights ongoing challenges with revenue and profitability. While there are positive steps towards financial improvement, significant issues remain, including revenue declines and increased losses.
Q2-2025 Updates
Positive Updates
Sequential Revenue Growth
15% growth on a quarter-over-quarter basis in Q2, driven by strong execution in a challenging environment with mid-teens growth in both the U.S. and international markets.
Cash System Sales Increase
Cash system sales in the U.S. represented 65% of total U.S. system sales in Q2 compared to 58% last year, indicating a strategic shift towards higher quality cash revenues.
Strategic Sale of Venous Hair Business
Definitive agreement to sell the Venous Hair business to Meta Health Group for $20 million, expected to improve revenue growth, lower operating expenses, and enhance cash flow.
Debt Reduction and Financing Progress
Significant progress in improving the balance sheet with cash and cash equivalents of $4.9 million and total debt obligations reduced to approximately $34.3 million.
Negative Updates
Year-over-Year Revenue Decline
Second quarter revenue declined 5% year-over-year, with international sales dropping 18%.
Gross Profit and Margin Declines
Gross profit decreased by 20% to $9.4 million, and gross margin fell to 60.1% from 71.5% due to economic uncertainties and supply disruptions.
Increased Operating Expenses and Losses
Total operating expenses increased by 6% to $18.5 million, with a GAAP operating loss of $9.0 million compared to $5.6 million in the prior year.
No Financial Guidance for 2025
Due to market conditions and ongoing strategic evaluations, the company is not providing full year 2025 financial guidance.
Company Guidance
During the second quarter of 2025, Venus Concept Inc. experienced notable financial movements, reporting a quarter-over-quarter revenue growth of 15%, driven by a 20% increase in total systems and subscription revenue, despite a 5% year-over-year decline in total revenue to $15.7 million. The company faced a challenging environment with an 18% decrease in international sales, offset by a 5% increase in U.S. sales, where cash system sales rose by 23% year-over-year. Gross profit dropped by 20% to $9.4 million, with a gross margin of 60.1%, influenced by economic uncertainties and supply disruptions. Notably, operating expenses increased by 6% to $18.5 million, leading to a GAAP operating loss of $9.0 million. However, the net loss narrowed to $11.7 million, or $8.03 per share, compared to $20.0 million, or $30.93 per share, the previous year. The company strategically sold its Venus Hair business for $20 million to focus on its medical aesthetics segment and improve financial health. Despite these challenges, Venus Concept is actively managing its cash burn and pursuing strategic alternatives to maximize shareholder value, although it refrained from providing full-year 2025 financial guidance.

Venus Concept Financial Statement Overview

Summary
Venus Concept faces significant financial challenges, with declining revenues, high operational costs, and substantial net losses. The balance sheet shows high leverage and low equity, posing risks to financial stability. Cash flow management remains a concern despite some improvement in free cash flow.
Income Statement
30
Negative
Venus Concept's income statement reveals significant challenges. The company has experienced declining revenue over the past few years, with a TTM revenue growth rate of -1.46%. Profitability metrics are concerning, with a TTM net profit margin of -81.26% and negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue. Despite a relatively strong gross profit margin of 67.90% in the TTM period, the overall financial health is weakened by substantial net losses.
Balance Sheet
25
Negative
The balance sheet highlights financial instability, with a very high debt-to-equity ratio of 17.05 in the TTM period, suggesting significant leverage and potential risk in meeting debt obligations. The return on equity is negative, reflecting losses and poor returns for shareholders. The equity ratio is low, indicating a heavy reliance on debt financing. These factors point to financial vulnerability and potential liquidity issues.
Cash Flow
35
Negative
Cash flow analysis shows some improvement in free cash flow growth, with a TTM growth rate of 29.09%. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is -0.41, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive at 1.01, suggesting that free cash flow is marginally covering net losses. Overall, cash flow management remains a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue60.11M64.83M76.35M99.50M105.62M78.01M
Gross Profit39.00M44.31M52.17M65.97M74.09M51.39M
EBITDA-32.31M-36.04M-26.11M-35.28M-13.04M-68.49M
Net Income-41.34M-47.00M-37.25M-43.58M-23.01M-82.82M
Balance Sheet
Total Assets63.09M68.18M93.65M125.38M157.37M160.53M
Cash, Cash Equivalents and Short-Term Investments3.88M4.27M5.40M11.57M30.88M34.30M
Total Debt37.06M43.03M79.70M83.77M77.87M79.60M
Total Liabilities60.31M65.35M107.10M116.64M112.27M116.76M
Stockholders Equity2.33M2.37M-14.02M8.09M40.94M44.23M
Cash Flow
Free Cash Flow-18.89M-11.19M-12.97M-27.32M-20.28M-28.94M
Operating Cash Flow-18.61M-11.07M-12.86M-26.98M-19.77M-28.65M
Investing Cash Flow-273.00K-123.00K-116.00K-336.00K-552.00K-2.39M
Financing Cash Flow18.02M10.06M6.80M8.01M16.82M49.67M

Venus Concept Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.43
Price Trends
50DMA
2.38
Positive
100DMA
2.42
Negative
200DMA
2.93
Negative
Market Momentum
MACD
<0.01
Negative
RSI
57.80
Neutral
STOCH
55.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERO, the sentiment is Positive. The current price of 2.43 is above the 20-day moving average (MA) of 2.32, above the 50-day MA of 2.38, and below the 200-day MA of 2.93, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.80 is Neutral, neither overbought nor oversold. The STOCH value of 55.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERO.

Venus Concept Risk Analysis

Venus Concept disclosed 46 risk factors in its most recent earnings report. Venus Concept reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Venus Concept Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
45
Neutral
$9.45M-0.43-4272.16%-66.40%65.99%
44
Neutral
$2.90M-0.09-162.70%-7.72%99.54%
42
Neutral
$11.23M-0.39-283.10%-40.47%96.14%
41
Neutral
$4.52M-1371.21%-13.90%44.89%
40
Underperform
$7.25M-0.1965.72%
37
Underperform
$3.70M-0.01-19.81%93.32%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VERO
Venus Concept
2.42
-3.08
-56.00%
NUWE
Nuwellis
3.32
-58.84
-94.66%
SINT
Sintx Technologies
4.11
0.89
27.64%
HIND
Vyome Holdings
5.36
-499.96
-98.94%
HSCS
Heart Test Laboratories, Inc.
3.69
-0.70
-15.95%
AMIX
Autonomix Medical, Inc.
1.17
-10.45
-89.93%

Venus Concept Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Venus Concept Secures Financial Relief with New Agreements
Positive
Sep 3, 2025

On August 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to address liquidity requirements and loan maturity dates. The Consent Agreement waived certain minimum liquidity requirements under the MSLP Loan Agreement through September 30, 2025, while the Nineteenth Bridge Loan Amendment extended the maturity date of the Bridge Loan to September 30, 2025. Additionally, the Notes Consent Agreement waived liquidity requirements under the 2025 Notes, also through September 30, 2025. These agreements are aimed at providing financial relief and operational flexibility to Venus Concept Inc.

Private Placements and FinancingBusiness Operations and Strategy
Venus Concept Secures $2M Loan for Operations
Neutral
Aug 26, 2025

Venus Concept Inc. announced the completion of its eleventh delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, amounting to $2,000,000, on August 21, 2025. This funding is intended for general working capital purposes, reflecting the company’s ongoing efforts to secure financial stability and support its operations in the competitive medical aesthetics industry.

Private Placements and FinancingBusiness Operations and Strategy
Venus Concept Amends Loan Agreements for Financial Relief
Neutral
Aug 6, 2025

On July 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to amend existing loan agreements, including waiving certain liquidity requirements and extending maturity dates. These amendments, including the Eighteenth Bridge Loan Amendment on August 6, 2025, aim to provide financial relief and operational flexibility, impacting the company’s financial strategy and stakeholder interests.

Private Placements and Financing
Venus Concept Secures Additional $2M Bridge Financing
Positive
Jul 25, 2025

Venus Concept Inc. announced on July 21, 2025, the completion of its tenth delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, securing an additional $2,000,000 in bridge financing. This funding, part of a larger $23,237,906.85 financing agreement, will be used for general working capital, reinforcing the company’s financial stability and operational capacity in the competitive medical aesthetics market.

Private Placements and FinancingM&A TransactionsBusiness Operations and Strategy
Venus Concept Executes Debt-to-Equity Exchange Agreement
Positive
Jul 1, 2025

On June 30, 2025, Venus Concept Inc. executed a debt-to-equity exchange agreement with Madryn Health Partners, converting $6.5 million of subordinated convertible notes into 325,651 shares of Series Y preferred stock. This transaction reduced the company’s total debt by 14% to approximately $34.3 million, enhancing its financial flexibility and supporting its strategic transformation plan, including the divestiture of the Venus Hair business.

Shareholder MeetingsBusiness Operations and Strategy
Venus Concept Approves Key Proposals at Annual Meeting
Positive
Jun 26, 2025

On June 25, 2025, Venus Concept Inc. held its Annual and Special Meeting of Stockholders, where several key proposals were approved by the stockholders. These included the election of Class II Directors, the ratification of MNP LLP as the independent registered public accounting firm for 2025, and the approval of the issuance of common stock upon conversion of various series of preferred stock and convertible notes. The approvals reflect strategic decisions aimed at enhancing the company’s financial structure and governance.

Private Placements and Financing
Venus Concept Completes Direct Offering and Private Placement
Neutral
Jun 9, 2025

On June 6, 2025, Venus Concept Inc. announced a securities purchase agreement with institutional investors for a registered direct offering of 434,720 shares of common stock at $2.65 per share, raising approximately $1.15 million before expenses. This offering, which closed on June 9, 2025, also included a concurrent private placement of warrants to purchase up to 869,440 shares. The proceeds are intended for working capital and general corporate purposes, potentially impacting the company’s financial flexibility and market operations.

M&A Transactions
Venus Concept Sells Hair Business to Meta Healthcare
Neutral
Jun 6, 2025

On June 5, 2025, Venus Concept Inc. entered into an agreement to sell its Venus Hair Business to Meta Healthcare Group for $20 million in an all-cash transaction. This strategic move involves transferring hair restoration technologies and a manufacturing facility, with the transaction expected to close in the third quarter of 2025, pending regulatory approvals and other conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 02, 2025